Valuation — not yet established
No valuation for Evommune is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($115.5M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for Evommune
Create free account
No card required
Funding history
4 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Oct 2024 | Later Stage VC (Series C) | $115.5M | ▮ | ▮ |
| Mar 2023 | Later Stage VC | $57.5M | ▮ | ▮ |
| Aug 2021 | Later Stage VC | $81.8M | ▮ | ▮ |
| Jun 2020 | Early Stage VC | $12.5M | ▮ | ▮ |
How Evommune's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Evommune, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Evommune raised?
- Evommune has raised $115.5M in total funding across 4 recorded rounds.
- When did Evommune last raise?
- Evommune last raised in Oct 2024 (Later Stage VC (Series C)), raising $115.5M.